Figure 1From: Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesEnrolment and outcomes. VKA, Vitamin K antagonist.Back to article page